Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

MiPLA

From PsychonautWiki Archive
Revision as of 20:06, 24 October 2018 by >Unity (Subjective effects: Removed section)
Jump to navigation Jump to search

N-Methyl-N-isopropyllysergamide (also known as methylisopropyllysergamide, Lamide and MiPLA) is a novel psychedelic substance of the lysergamide class. MiPLA is chemically similar to LSD and has a similar mechanism of action, working primarily by stimulating serotonin receptors in the brain.

MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research into LSD. It has recently been researched in greater detail by by the team led by David E. Nichols at Purdue University. MiPLA and its effects are also mentioned in Alexander Shulgin's Pharmacology notes #9 and Pharmacology notes C,

User reports describe the effects of MiPLA as similar to those of LSD with major differences. It is thought to be 1/3rd as potent as LSD itself, with an active dose reported at between 100-200 micrograms. It is often described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides.

Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.

Chemistry

The chemical name of MiPLA is methylisopropyllysergamide. MiPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is LSD, lysergic acid diethylamide.

MiPLA is a structural isomer of LSD. Like LSD, the chemical structure of MiPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, MiPLA is substituted with a methyl and isopropyl group.

MiPLA is a chiral compound with two stereocenters at R5 and R8. The differences in psychoactivity between the stereoisomers has not been investigated.

The physical properties of MiPLA have not been documented in the scientific literature.

Pharmacology

Subjective effects

MiPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Experience reports

There are currently 1 anecdotal reports which describe the effects of this compound within our experience index.

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational MiPLA use has not been studied in any scientific context and the exact toxic dose is unknown. This is because MiPLA is a research chemical with very little history of human usage.

The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute MiPLA exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, MiPLA is able to be considered non-addictive, with an extremely low toxicity relative to dose.[1] It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute MiPLA exposure.

However, as with LSD and psychedelics in general, it is possible that MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Dependence and abuse potential

Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, MiPLA is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of MiPLA are built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). MiPLA presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the use of MiPLA all psychedelics will have a reduced effect.

Owing to its activity at the 5-HT2A receptor, MiPLA presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of MiPLA all psychedelics will have a reduced effect.

Overdose

The LD50 of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of MiPLA.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

MiPLA is currently a gray area compound within most parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.

  • Austria: MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. [citation needed]
  • United States: MiPLA is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.

See also

Discussion

Literature

References

  1. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The Pharmacology of Lysergic Acid Diethylamide: A Review, 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x
  2. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089